Industry News (Animal Models)

Animal Model Will Be Used To Test Hepatitis C Therapies

Published in Hepatitis Weekly, November 29th, 1999

XTL Biopharmaceuticals Ltd. and F. Hoffmann-La Roche Ltd. announced the signing of an agreement to evaluate therapeutics for hepatitis C (HCV). Under the agreement, Roche will use XTL's proprietary Trimera(XTL) animal model to test Roche's HCV compounds.

According to Martin Becker, PhD, XTL, "XTL's Trimera(XTL) HCV disease model offers drug development companies a breakthrough, in vivo system that could significantly accelerate the development and commercialization of new drugs to treat hepatitis C, a serious infectious disease that is responsible for an estimated 8,000 deaths annually in the U.S."

The companies will use XTL's Trimera(XTL) system,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1999-11-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry